Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696271 | 0.97 | DGAT1 (0.41) | DGAT1CYP2C19RIPK1AKR1C1FFAR3 | |
| Hydrochloric Acid SCHEMBL12479454 | 0.95 | DGAT1 (0.40) | DGAT1CYP2C19RIPK1AKR1C1 | |
| SCHEMBL17586 | 0.95 | DGAT1 (0.43) | DGAT1CYP2C19RIPK1FFAR3 | |
| SCHEMBL18559 | 0.89 | DGAT1 (0.52) | DGAT1FFAR3 | |
| Hydrochloric Acid SCHEMBL23094114 | 0.86 | DGAT1 (0.50) | DGAT1FFAR3 | |
| SCHEMBL28167619 | 0.81 | DGAT1 (0.44) | DGAT1RIPK1 | |
| SCHEMBL9446531 | 0.79 | DGAT1 (0.43) | DGAT1CYP2C19RIPK1 | |
| SCHEMBL27474067 | 0.79 | DGAT1 (0.43) | DGAT1RIPK1 | |
| SCHEMBL21826042 | 0.78 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL25325201 | 0.78 | DGAT1 (0.43) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| CN-111162313-A | Polymer electrolyte and lithium ion battery | 珠海冠宇电池有限公司 | 2020-05-15 | — | — | CN | claimed |
| EP-3802500-B1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12492182-B2 | Hydroxytriazine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2025-12-09 | — | — | US | disclosed |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4550995-A2 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3492528-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025048759-A1 | BENZIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS | ICOSYN THERAPEUTICS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025026158-A1 | COMPOUNDS HAVING PTPN2 INHIBITORY EFFECTS AND USE THEREOF | 杭州中美华东制药有限公司 | 2025-02-06 | — | — | WO | disclosed |
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | SIRONAX LTD (KY) | 2024-10-29 | — | — | US | disclosed |
| CN-112533904-B | Melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| EP-2504317-A1 | POTASSIUM CHANNEL MODULATORS | Abbott Laboratories (US) | 2012-10-03 | — | — | EP | disclosed |
| CN-102666495-A | Potassium channel modulators | ABBOTT LAB | 2012-09-12 | — | — | CN | disclosed |
| WO-2011066168-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885CYP2C19 692/4885RIPK1 3322/4885 |
| US-12492182-B2 | Hydroxytriazine compounds and pharmaceutical use thereof | PTGS1, PTGIS, PTGES | DGAT1 1971/4885CYP2C19 2002/4885RIPK1 2493/4885 |
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | RIPK1, RIPK3, RIPK4 | DGAT1 844/4885CYP2C19 4335/4885RIPK1 1/4885 |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | DGAT1 2527/4885CYP2C19 2407/4885RIPK1 2626/4885 |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | DGAT1 3220/4885CYP2C19 1504/4885RIPK1 4491/4885 |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | DGAT1 3952/4885CYP2C19 3420/4885RIPK1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.